Global Ganja Report

Starting July 6, the International Cannabinoid Research Society (ICRS) will hold its 21st annual symposium in St. Charles, Ill., just outside of Chicago. Notably, this year's symposium is sponsored by an array of pharmaceutical companies, the US National Institute on Drug Abuse (NIDA), and ElSohly Laboratories of Oxford, Miss., the federal government's only licensed source of research-grade cannabis.

Deputy US Attorney General James Cole issued a controversial memorandum June 29 in an attempt to clarify federal policy on medical marijuana. Calling cannabis "a dangerous drug," Cole's memo threatened enforcement actions against "Persons who are in the business of cultivating, selling or distributing marijuana, and those who knowingly facilitate such activities," including local and state officials. The memo further underscored that "State laws or local ordinances are not a defense to civil or criminal enforcement of federal law."

Jim Squatter was already a longtime veteran of the squatting, anti-nuclear and anarchist movements before a devastating accident turned him into a medical marijuana user—and a fighter for the right to medicinal cannabis.

A former cancer patient and the husband of an elderly woman with serious health problems told a district judge in Montana June 20 of their concerns about whether they can still obtain medical cannabis if a new law takes effect July 1 to ban commercial growing operations in the state. The testimony came in the first day of hearings in a lawsuit filed by the Montana Cannabis Industry Association and others asking Judge James Reynolds to issue an injunction to stop the law from taking effect. 

The Colorado Board of Health on June 15 adopted new rules for the state's small-scale medical marijuana providers, over the objections of cannabis advocates who say the rules are too harsh. The rules require that caregivers—medical marijuana providers who by law must serve five or fewer patients—do more than just provide cannabis. They must now do something extra, such as help patients with shopping, cooking or getting to doctors' appointments. Medical marijuana advocates fear the added responsibilities will severely limit the number of caregivers, which today stands at 16,000 by official figures. (Denver Post, June 15; Sensible Colorado)

During last year's Prop 19 fight in California, we noted the strange phenomenon of "Stoners Against Legalization"—tokers who opposed the legalization measure, sometimes spouting bizarre conspiracy theories that the ballot initiative was all a plot by Monsanto and other big corporations to corner the cannabis market and squeeze out independent growers with bio-engineered patented varieties. We noted that even if Prop 19 passed, "cannabis will remain illegal at the federal level, allowing Monsanto to be shut down if they dabble in the Evil Weed." But now it emerges that—surprise, surprise!—the feds have actually been giving multi-national corporations the legal right to grow cannabis that us commoners are denied.

Three medical marijuana bills were introduced in Congress May 25 with support from patient advocates. The most significant of the three bills is one introduced by Rep. Barney Frank (D-MA), which would reclassify marijuana from its current status as a dangerous drug with no medical value. Another bill, introduced by Rep. Jared Polis (D-CO), will allow banks and other financial institutions to provide services to medical marijuana businesses without being subject to "suspicious activity" reporting requirements. The third bill, introduced by Rep. Pete Stark (D-CA), changes the federal tax code "to allow a deduction for expenses in connection with the trade or business of selling marijuana intended for patients for medical purposes pursuant to State law."

A coalition of advocacy groups and patients filed suit in the DC Circuit Court on May 23 to compel the Obama administration to answer a nine-year-old petition to reclassify medical marijuana. The Coalition for Rescheduling Cannabis (CRC) has never received an answer to its 2002 petition, despite a formal recommendation in 2006 from the Department of Health and Human Services (HHS) to the Drug Enforcement Administration (DEA), the final arbiter in the rescheduling process.